跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Hexal AG

首页临床试验发起方与机构Hexal AG

Hexal AG

ACTIVE

德国www.hexal.deSubsidiary成立于: 1986-01-01

隶属于诺华制药

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

111

96 进行中

药物批准

49

批准总数

监管机构

5

监管机构数

成立时间

1986

概览

试验阶段分布

阶段

试验数

占比

1 期

59

53.1%

3 期

5

4.5%

不适用

1

0.9%

试验状态分布

进行中（未招募）

93

83.8%

已完成

13

11.7%

尚未招募

3

2.7%

招募中

2

1.8%

相关临床试验

该机构主办的试验（111）

This is a comparative study of Nivolumab in participants with melanoma(skin cancer) requiring additional treatment with nivolumab.

Mar 2026150 名受试者

Safety study of GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer

Oct 20251038 名受试者

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants with Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Jan 2025720 名受试者

A study to compare efficacy, safety, and immunogenicity of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic non-squamous non-small cell lung cancer (NSCLC) (Jimmy-Lung)

Oct 202460 名受试者

Phase 3 study assessing the efficacy, safety and immunogenicity of SOK583A1 versus Eylea in patients with neovascular age related macular degeneration

Nov 2021460 名受试者

The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator

进行中（未招募）

May 2021460 名受试者

The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator

进行中（未招募）

Jan 2021460 名受试者

The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator

进行中（未招募）

Jan 2021460 名受试者

第 1 页，共 14 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

13

药物批准

EMA

European Medicines Agency

7

药物批准

PHILIPPINES

Philippines FDA

7

药物批准

SFDA

Saudi Food and Drug Authority

20

药物批准

NPRA

National Pharmaceutical Regulatory Agency

2

药物批准

近期批准

Fentanyl HEXAL MAT 50 mcg/h Transdermal Patch

Fentanyl HEXAL MAT 25 mcg/h Transdermal Patch

AMLOHOPE 10 mg/5 mg Capsule

AMLOHOPE 5 mg/10 mg Capsule

资讯

暂无资讯文章

本页目录

概览
相关临床试验111
药物批准49
资讯

返回机构列表